Yu J, Xu FQ. Clinical efficacy and safety of Guipi decoction combined with escitalopram oxalate tablets in patients with depression. World J Clin Cases 2023; 11(29): 7017-7025 [PMID: 37946779 DOI: 10.12998/wjcc.v11.i29.7017]
Corresponding Author of This Article
Feng-Quan Xu, MD, Associate Professor, Department of Psychosomatic Medicine, Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine, No. 5 Beixiange, Xicheng District, Beijing 100053, China. qazujm1258@163.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 16, 2023; 11(29): 7017-7025 Published online Oct 16, 2023. doi: 10.12998/wjcc.v11.i29.7017
Clinical efficacy and safety of Guipi decoction combined with escitalopram oxalate tablets in patients with depression
Jia Yu, Feng-Quan Xu
Jia Yu, Psychiatry Department, Beijing Changping Hospital of Traditional and Western Medicine, Beijing 102206, China
Feng-Quan Xu, Department of Psychosomatic Medicine, Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100053, China
Author contributions: Yu J proposed the concept of this study; Xu FQ collected the data; Yu J and Xu FQ contributed to formal analysis; Xu FQ and Yu J participated in the investigation; Yu J and Xu FQ contributed to the methodology; Yu led the study; Xu FQ validated the study; Xu FQ and Yu J contributed to the visualization of the research; Xu FQ and Yu J drafted the manuscript; Yu J and Xu FQ reviewed and edited the manuscript.
Institutional review board statement: The study was approved by the Ethics Committee of Beijing Changping Hospital of Traditional and Western Medicine.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors declare that there are no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng-Quan Xu, MD, Associate Professor, Department of Psychosomatic Medicine, Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine, No. 5 Beixiange, Xicheng District, Beijing 100053, China. qazujm1258@163.com
Received: July 12, 2023 Peer-review started: July 12, 2023 First decision: August 2, 2023 Revised: August 5, 2023 Accepted: September 18, 2023 Article in press: September 18, 2023 Published online: October 16, 2023
Core Tip
Core Tip: The combination of Guipi decoction and escitalopram oxalate tablets showed promising clinical benefits for individuals with depression. In this study involving 80 patients who were divided into either an experimental group or a control group, the experimental group receiving both treatments exhibited significantly lower Traditional Chinese medicine (TCM) syndrome scores compared to the control group. After treatment, both groups experienced notable reductions in self-rating depression scale and Hamilton depression rating scale scores, with the experimental group showing greater improvement. The total treatment efficiency was significantly better in the experimental group. Additionally, both groups demonstrated improved sleep quality based on Pittsburgh sleep quality index scores. The experimental group had a lower incidence of adverse reactions compared to the control group. These findings indicate that the combined therapy effectively reduced TCM syndrome scores, improved depressive symptoms, and enhanced sleep quality in patients with depression. Thus, Guipi decoction combined with escitalopram oxalate tablets demonstrates potential as a safe and effective treatment option for depression, warranting further research and consideration in clinical practice.
